Habiro K, Mease PJ, et al. Efficacy and Safety of TYK2 Inhibitor Deucravacitinib in Patients With Active Psoriatic Arthritis: Global Phase 2 Clinical Study. This evidence concerns the gene TYK2 and psoriatic arthritis.